FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Communiqués Frazier Lifesciences Acquisition Corporation

Actions

NAMS

NL00150012L7

Recherche biotechnologique et médicale

Temps réel estimé Tradegate 16:31:52 02/10/2026			Varia. 5j.	Varia. 1 janv.
21,30 ^EUR	-10,52%		+4,71%	-32,13%

29/09	NewAmsterdam Pharma administre le traitement au premier participant de son essai de phase 2b sur la maladie d’Alzheimer préclinique	MT
29/09	NewAmsterdam Pharma Company N.V. Administre le traitement au premier participant de l’essai de phase 2b SPINOZA évaluant l’obicét rapid dans la maladie d’Alzheimer préclinique	CI

Communiqués

29/09	NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease	GL
21/09	NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)	GL
21/09	NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)	AQ
04/09	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
03/09	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
02/09	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September	GL
26/08	NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026	GL
06/08	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
05/08	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results	GL
29/07	NewAmsterdam Pharma to Host Investor Day on August 5, 2026	GL
27/07	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo and Evlarco	AQ
24/07	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)	GL
08/07	Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma	AQ
02/07	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
01/07	NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026	GL
03/06	NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions	GL
03/06	NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions	AQ
28/05	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June	GL
11/05	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May	GL
07/05	Frazier Lifesciences Acquisition : NewAmsterdam Pharma PREVAIL Update May 2026	PU
07/05	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	GL
07/05	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	AQ
01/05	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
08/04	NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference	GL
08/04	NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ